SCHEMBL6176258

SCHEMBL6176258

CC1(C)CCC(C)(C)c2nc(C=O)cnc21

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RARB P10826 8/20 0.41
RARA P10276 7/20 0.41
RARG P13631 7/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175740 0.89 RARA (0.33) RARBRARARARG
SCHEMBL6176106 0.78
SCHEMBL6177623 0.78
SCHEMBL13450327 0.74 RARB (0.43) RARBRARARARG
SCHEMBL6017295 0.74 RARB (0.39) RARBRARARARG
SCHEMBL6175908 0.71 RARB (0.44) RARBRARARARG
SCHEMBL6177290 0.70 RARB (0.62) RARBRARARARG
SCHEMBL4431042 0.70 RARB (0.55) RARBRARARARG
SCHEMBL7668584 0.69 RARB (0.44) RARBRARARARG
SCHEMBL7674828 0.67 RARB (0.54) RARBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000631-A1 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION UNIVERSITY OF DURHAM (GB) 2026-01-01 US disclosed
US-12344587-B2 Synthetic retinoids for use in RAR activation UNIVERSITY OF DURHAM (GB) 2025-07-01 US disclosed
EP-4414355-A2 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION University of Durham (GB) 2024-08-14 EP disclosed
EP-3937923-B1 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION UNIV DURHAM (GB) 2024-07-24 EP disclosed
US-20220144783-A1 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION UNIVERSITY OF DURHAM (GB) 2022-05-12 US disclosed
EP-3937923-A2 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION University Of Durham (GB) 2022-01-19 EP disclosed
CN-113677667-A Synthetic retinoids for RAR activation 杜伦大学 2021-11-19 CN disclosed
WO-2020183173-A2 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION UNIVERSITY OF DURHAM (GB) 2020-09-17 WO disclosed
EP-1559709-A1 Heterocycle-containing carboxylic acid derivative and drug containing the same Eisai Co., Ltd. (JP) 2005-08-03 EP disclosed
EP-0838453-B1 HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME EISAI CO LTD (JP) 2005-04-27 EP disclosed
US-6884808-B2 Heterocycle-containing carboxylic acid derivative and drug containing the same EISAI CO. LTD. (JP) 2005-04-26 US disclosed
US-6630463-B2 Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia EISAI CO. LTD. (JP) 2003-10-07 US disclosed
US-20030144276-A1 Heterocycle-containing carboxylic acid derivative and drug containing the same EISAI CO. LTD. 2003-07-31 US disclosed
US-6541474-B2 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia EISAI CO. LTD. (JP) 2003-04-01 US disclosed
US-20020103234-A1 Heterocycl-containing carboxylic acid derivative and drug containing the same EISAI CO. LTD. 2002-08-01 US disclosed
US-20020032202-A1 Heterocycle-containing carboxylic acid derivative and drug containing the same EISAI CO. LTD. 2002-03-14 US disclosed
US-6329402-B1 FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA EISAI CO., LTD. (JP) 2001-12-11 US disclosed
US-5977108-A LEUKEMIA EISAI CO., LTD (JP) 1999-11-02 US disclosed
EP-0838453-A1 HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 1998-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103234-A1 Heterocycl-containing carboxylic acid derivative and drug containing the same RARA, RARB, RARG RARB 2/4885RARA 1/4885RARG 3/4885
US-20260000631-A1 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION RARB, RARA, RXRA RARB 1/4885RARA 2/4885RARG 5/4885
US-20030144276-A1 Heterocycle-containing carboxylic acid derivative and drug containing the same RARA, RARB, RARG RARB 2/4885RARA 1/4885RARG 3/4885
US-20220144783-A1 SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION RARA, RXRA, RARB RARB 3/4885RARA 1/4885RARG 4/4885
US-12344587-B2 Synthetic retinoids for use in RAR activation RARA, RXRA, RARB RARB 3/4885RARA 1/4885RARG 4/4885
US-20020032202-A1 Heterocycle-containing carboxylic acid derivative and drug containing the same RARA, RARB, RARG RARB 2/4885RARA 1/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.